Valuation: Castle Biosciences, Inc.

Market Cap 719M 629M 580M 536M 1.02B 68.61B 1.03B 6.94B 2.72B 33.8B 2.7B 2.64B 116B P/E 2026 *
-16.9x
P/E 2027 * -25.4x
Enterprise Value 719M 629M 580M 536M 1.02B 68.61B 1.03B 6.94B 2.72B 33.8B 2.7B 2.64B 116B EV / Sales 2026 *
2.04x
EV / Sales 2027 * 1.83x
Free-Float
97.27%
Yield 2026 *
-
Yield 2027 * -
1 day-3.42%
1 week-1.62%
Current month-0.55%
1 month+12.90%
3 months+2.55%
6 months-39.71%
Current year-39.02%
1 week 23.34
Extreme 23.34
24.8
1 month 19.86
Extreme 19.855
24.98
Current year 17.72
Extreme 17.722
44.28
1 year 14.59
Extreme 14.59
44.28
3 years 12.07
Extreme 12.07
44.28
5 years 9.26
Extreme 9.2601
78.58
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 01/09/2007
Director of Finance/CFO 56 01/12/2017
Chief Tech/Sci/R&D Officer - 01/07/2021
Director TitleAgeSince
Director/Board Member 64 01/09/2007
Chairman 64 01/09/2014
Director/Board Member 70 06/12/2018
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

Founder

22,264 0.0734%
07-01Sell

Chief Operating Officer

-8,586 0.0283%
06-16Sell

Chief Operating Officer

-8,587 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
-3.42%-1.62%+20.65%+20.53% 719M
-2.46%-4.72%+218.51%+319.86% 21.22B
-2.58%+0.14%-41.49%-24.31% 9.41B
-0.33%-3.87%+29.92%+26.65% 6.88B
-0.86%+9.54%+233.83%-27.04% 5.42B
+3.74%-1.63%-21.04%-28.49% 5.05B
-4.92%-7.16%-35.91% - 4.8B
-1.04%-1.40%-24.07%-25.45% 4.17B
+0.75%-11.50%+60.48%+68.63% 3.64B
+0.62%-0.77%-18.68%-43.44% 2.59B
Average -1.05%-1.10%+42.22%+31.88% 6.39B
Weighted average by Cap. -1.42%-1.75%+86.50%+109.93%

Financials

2026 *2027 *
Net sales 353M 308M 285M 263M 499M 33.64B 507M 3.4B 1.34B 16.57B 1.32B 1.3B 56.97B 393M 344M 317M 293M 556M 37.53B 566M 3.79B 1.49B 18.49B 1.48B 1.45B 63.55B
Net income -43.46M -38.02M -35.07M -32.39M -61.46M -4.15B -62.49M -419M -165M -2.04B -163M -160M -7.02B -26.06M -22.79M -21.02M -19.42M -36.84M -2.49B -37.46M -251M -98.64M -1.22B -97.84M -95.71M -4.21B
Net Debt - -
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
942
Date Price Change Volume
10/07/26 $23.72 -3.42% 207,334
09/07/26 $24.56 +3.89% 262,629
08/07/26 $23.64 -0.80% 413,163
07/07/26 $23.83 -1.57% 234,221
06/07/26 $24.21 +0.41% 209,118
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
23.72USD
Average target price
43.56USD
Spread / Average Target
+83.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSTL Stock